BioLargo EBITDA vs. Shares Owned By Insiders

BLGO Stock  USD 0.20  0.01  5.26%   
Considering BioLargo's profitability and operating efficiency indicators, BioLargo may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess BioLargo's ability to earn profits and add value for shareholders.
For BioLargo profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioLargo to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioLargo utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioLargo's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioLargo over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between BioLargo's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioLargo is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioLargo's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

BioLargo Shares Owned By Insiders vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining BioLargo's current stock value. Our valuation model uses many indicators to compare BioLargo value to that of its competitors to determine the firm's financial worth.
BioLargo is rated below average in ebitda category among its peers. It is rated fifth in shares owned by insiders category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value BioLargo by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioLargo's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

BioLargo Shares Owned By Insiders vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

BioLargo

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(6.64 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

BioLargo

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
14.70 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

BioLargo Shares Owned By Insiders Comparison

BioLargo is currently under evaluation in shares owned by insiders category among its peers.

BioLargo Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in BioLargo, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioLargo will eventually generate negative long term returns. The profitability progress is the general direction of BioLargo's change in net profit over the period of time. It can combine multiple indicators of BioLargo, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California. Biolargo operates under Chemicals classification in the United States and is traded on OTC Exchange. It employs 31 people.

BioLargo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on BioLargo. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioLargo position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioLargo's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in BioLargo without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run AI Portfolio Architect Now

   

AI Portfolio Architect

Use AI to generate optimal portfolios and find profitable investment opportunities
All  Next Launch Module

Use Investing Themes to Complement your BioLargo position

In addition to having BioLargo in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Conservative Funds Thematic Idea Now

Conservative Funds
Conservative Funds Theme
Funds or Etfs that invest using buy-and-hold investment strategy in companies with consistent growth over many years of operation. The Conservative Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Conservative Funds Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in BioLargo OTC Stock

To fully project BioLargo's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BioLargo at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BioLargo's income statement, its balance sheet, and the statement of cash flows.
Potential BioLargo investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although BioLargo investors may work on each financial statement separately, they are all related. The changes in BioLargo's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioLargo's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.